Investigational combination therapy CagriSema demonstrated significant weight reduction and noninferior HbA1c lowering in phase 3 clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results